JP2007500129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500129A5 JP2007500129A5 JP2006521269A JP2006521269A JP2007500129A5 JP 2007500129 A5 JP2007500129 A5 JP 2007500129A5 JP 2006521269 A JP2006521269 A JP 2006521269A JP 2006521269 A JP2006521269 A JP 2006521269A JP 2007500129 A5 JP2007500129 A5 JP 2007500129A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- methyl
- alkyl
- aryl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- -1 —OR 4 Chemical group 0.000 claims description 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 230000036407 pain Effects 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000028709 inflammatory response Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- DOZPMYMBJUTOGT-UHFFFAOYSA-N 3-(3-acetamido-4-benzoylphenyl)-n-cyclopropyl-4-methylbenzamide Chemical compound CC(=O)NC1=CC(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)=CC=C1C(=O)C1=CC=CC=C1 DOZPMYMBJUTOGT-UHFFFAOYSA-N 0.000 claims 1
- ZCRPREDQMGUQIX-UHFFFAOYSA-N 3-(3-amino-4-benzoylphenyl)-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(C=C1N)=CC=C1C(=O)C1=CC=CC=C1 ZCRPREDQMGUQIX-UHFFFAOYSA-N 0.000 claims 1
- ZQDKOTPZLQHPBR-UHFFFAOYSA-N 3-(3-benzyl-4-oxoquinazolin-7-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(C=1)=CC=C(C2=O)C=1N=CN2CC1=CC=CC=C1 ZQDKOTPZLQHPBR-UHFFFAOYSA-N 0.000 claims 1
- DWDYREIPSKKNNK-UHFFFAOYSA-N 3-(4-benzoylphenyl)-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 DWDYREIPSKKNNK-UHFFFAOYSA-N 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- IJADXUNGOPLGGJ-UHFFFAOYSA-N 6-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-[(4-methoxyphenyl)methyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 IJADXUNGOPLGGJ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 241000713730 Equine infectious anemia virus Species 0.000 claims 1
- 241000713800 Feline immunodeficiency virus Species 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 241000175212 Herpesvirales Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- UTTGLYGDNDKJJN-UHFFFAOYSA-N O=C(NC1CC1)c1cccc(-c2ccccc2)c1N1NC=CO1 Chemical compound O=C(NC1CC1)c1cccc(-c2ccccc2)c1N1NC=CO1 UTTGLYGDNDKJJN-UHFFFAOYSA-N 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000005074 Retroviridae Infections Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000002257 antimetastatic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 229930194791 calphostin Natural products 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229960002706 gusperimus Drugs 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000011379 keloid formation Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 208000021601 lentivirus infection Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims 1
- PWKFZWLBMJRKFH-UHFFFAOYSA-N n-cyclopropyl-3-[3-[(2,6-dichlorophenyl)methyl]-4-oxoquinazolin-7-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(C=1)=CC=C(C2=O)C=1N=CN2CC1=C(Cl)C=CC=C1Cl PWKFZWLBMJRKFH-UHFFFAOYSA-N 0.000 claims 1
- KGPJPLBEAMXAEJ-UHFFFAOYSA-N n-cyclopropyl-3-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-7-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(C=1)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C(Cl)=C1 KGPJPLBEAMXAEJ-UHFFFAOYSA-N 0.000 claims 1
- QPZAZKMAJLIKAX-UHFFFAOYSA-N n-cyclopropyl-3-[3-[(4-methoxyphenyl)methyl]-4-oxoquinazolin-7-yl]-4-methylbenzamide Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C2=CC=C(C=3C(=CC=C(C=3)C(=O)NC3CC3)C)C=C2N=C1 QPZAZKMAJLIKAX-UHFFFAOYSA-N 0.000 claims 1
- GLBORQOWZPWKSD-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-(2-oxo-4-phenyl-1h-quinazolin-7-yl)benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(C=C1NC(=O)N=2)=CC=C1C=2C1=CC=CC=C1 GLBORQOWZPWKSD-UHFFFAOYSA-N 0.000 claims 1
- LDFYACGKGVSHAE-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-(4-oxo-1h-quinazolin-7-yl)benzamide Chemical compound C1=C(C=2C=C3C(C(NC=N3)=O)=CC=2)C(C)=CC=C1C(=O)NC1CC1 LDFYACGKGVSHAE-UHFFFAOYSA-N 0.000 claims 1
- YOEPYRRTMCNYCD-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-(4-phenylquinazolin-7-yl)benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(C=C1N=CN=2)=CC=C1C=2C1=CC=CC=C1 YOEPYRRTMCNYCD-UHFFFAOYSA-N 0.000 claims 1
- IPTFJBXBPWQGAI-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-(1h-1,2,4-triazol-5-yl)phenyl]benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(C=C1)=CC=C1C1=NN=CN1 IPTFJBXBPWQGAI-UHFFFAOYSA-N 0.000 claims 1
- FHWHYNJCNGPMDV-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]benzamide Chemical compound O1C(C)=NN=C1C1=CC=C(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C=C1 FHWHYNJCNGPMDV-UHFFFAOYSA-N 0.000 claims 1
- IGADKXNUGPMKMO-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[5-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-2-yl]benzamide Chemical compound O1C(C)=NN=C1C1=CC=C(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 IGADKXNUGPMKMO-UHFFFAOYSA-N 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 229960003753 nitric oxide Drugs 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 1
- 229950005741 rolipram Drugs 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 claims 1
- 229960003676 tenidap Drugs 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 125000005239 aroylamino group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49009603P | 2003-07-25 | 2003-07-25 | |
| PCT/US2004/023726 WO2005012241A2 (en) | 2003-07-25 | 2004-07-23 | p-38 KINASE INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500129A JP2007500129A (ja) | 2007-01-11 |
| JP2007500129A5 true JP2007500129A5 (enExample) | 2007-09-06 |
Family
ID=34115357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521269A Ceased JP2007500129A (ja) | 2003-07-25 | 2004-07-23 | ｐ−３８キナーゼ阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7700622B2 (enExample) |
| EP (3) | EP1687284B1 (enExample) |
| JP (1) | JP2007500129A (enExample) |
| CN (2) | CN101337944A (enExample) |
| AT (2) | ATE412642T1 (enExample) |
| AU (2) | AU2004261589B2 (enExample) |
| BR (1) | BRPI0412918A (enExample) |
| CA (1) | CA2534990A1 (enExample) |
| DE (2) | DE602004029293D1 (enExample) |
| ES (1) | ES2315703T3 (enExample) |
| MX (1) | MXPA06000915A (enExample) |
| PL (1) | PL1687284T3 (enExample) |
| PT (1) | PT1687284E (enExample) |
| WO (1) | WO2005012241A2 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ES2295553T3 (es) | 2002-02-12 | 2008-04-16 | Smithkline Beecham Corporation | Derivados de nicotinamida utiles como inhibidores de p38. |
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| EP1669348A4 (en) * | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| JPWO2006016548A1 (ja) * | 2004-08-09 | 2008-05-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環化合物を含有する新規な抗マラリア剤 |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
| WO2006044975A2 (en) * | 2004-10-19 | 2006-04-27 | Compass Pharmaceuticals Llc | Compositions and their use as anti-tumor agents |
| US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| US7829585B2 (en) * | 2005-03-30 | 2010-11-09 | Eisai R&D Management Co., Ltd. | Antifungal agent containing pyridine derivative |
| GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
| RU2452729C2 (ru) * | 2005-09-16 | 2012-06-10 | Арроу Терапьютикс Лимитед | Бифенильные производные и их применение при лечении гепатита с |
| AU2006290442B2 (en) * | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
| TWI385169B (zh) * | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| WO2007064932A2 (en) * | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc. | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| WO2007100880A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| MX2008014990A (es) * | 2006-05-30 | 2008-12-09 | Arrow Therapeutics Ltd | Derivados de bifenilo y su uso en el tratamiento de hepatitis c. |
| ES2400695T3 (es) * | 2006-07-17 | 2013-04-11 | Amgen Inc. | Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38 |
| RU2009106722A (ru) * | 2006-07-28 | 2010-09-10 | Новартис АГ (CH) | 2,4-замещенные хиназолины в качестве ингибиторов липидной киназы |
| EP2065377B1 (en) * | 2006-09-21 | 2011-11-23 | Eisai R&D Management Co., Ltd. | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
| WO2008050808A1 (fr) * | 2006-10-24 | 2008-05-02 | Kyowa Hakko Kirin Co., Ltd. | Dérivé de 2-aminoquinazoline |
| EP2097085A4 (en) * | 2006-11-27 | 2010-02-10 | Ariad Pharma Inc | THERAPEUTIC MATERIALS AND METHOD |
| US8263588B2 (en) | 2007-04-06 | 2012-09-11 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| ES2534573T3 (es) | 2007-04-06 | 2015-04-24 | Neurocrine Biosciences, Inc. | Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos |
| TW200841879A (en) * | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
| CN101622251B (zh) | 2007-04-27 | 2012-07-04 | 卫材R&D管理有限公司 | 杂环取代吡啶衍生物的盐或其结晶 |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| AU2008276451A1 (en) * | 2007-07-17 | 2009-01-22 | Zalicus Inc. | Treatments of B-cell proliferative disorders |
| US20090047243A1 (en) * | 2007-07-17 | 2009-02-19 | Richard Rickles | Combinations for the treatment of b-cell proliferative disorders |
| WO2009034390A1 (en) * | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
| KR100916716B1 (ko) * | 2007-09-27 | 2009-09-10 | 한국화학연구원 | 3-클로로-5-치환-퀴녹살린-2-아민 유도체 및 약제학적으로허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제 |
| US8513287B2 (en) * | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| US20100009934A1 (en) * | 2008-06-09 | 2010-01-14 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| US8188119B2 (en) * | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
| JP2012176900A (ja) * | 2009-06-24 | 2012-09-13 | Eisai R & D Management Co Ltd | （（ホスホノオキシ）メチル）ピリジニウム環を有するピリジン誘導体およびそれらを含有する抗真菌剤 |
| CN102120990A (zh) * | 2010-03-15 | 2011-07-13 | 中国人民解放军军事医学科学院基础医学研究所 | 人p38α与TAB1新功能表位以及用途 |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| CN103524431B (zh) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用 |
| EP3061749B1 (en) * | 2013-10-23 | 2019-02-27 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
| CN104961803B (zh) * | 2015-07-08 | 2017-11-28 | 中国人民解放军军事医学科学院基础医学研究所 | 一种治疗心肌缺血再灌注损伤的多肽药物 |
| CN104961804B (zh) * | 2015-07-08 | 2017-12-01 | 中国人民解放军军事医学科学院基础医学研究所 | p38α拮抗肽突变体及其应用 |
| KR101879481B1 (ko) * | 2015-08-31 | 2018-07-17 | 경희대학교 산학협력단 | 벤조페논 유도체, 이의 제조방법 및 이를 포함하는 항염증 약학적 조성물 |
| US10550073B2 (en) * | 2015-09-30 | 2020-02-04 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Benzamide derivative |
| ES2952744T3 (es) | 2016-12-15 | 2023-11-03 | Nestle Sa | Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía |
| KR102114394B1 (ko) * | 2017-08-30 | 2020-05-22 | 경희대학교 산학협력단 | 벤조페논 유도체, 이의 제조방법 및 이를 포함하는 b형간염 치료용 약학적 조성물 |
| CN111183957A (zh) * | 2020-02-19 | 2020-05-22 | 中国医科大学附属第一医院 | 一种减轻自身免疫甲状腺炎模型的构建方法及其应用 |
| KR102624481B1 (ko) * | 2020-03-20 | 2024-01-16 | (주)프레이저테라퓨틱스 | p38 제거능을 갖는 화합물, 이의 제조방법 및 이를 포함하는 만성 염증성 질환 치료용 조성물 |
| KR102298450B1 (ko) * | 2021-01-29 | 2021-09-08 | (주)프레이저테라퓨틱스 | p38 MAP 키나아제 억제제로 항염증 활성을 나타내는 신규 화합물 |
| KR102314026B1 (ko) * | 2021-07-06 | 2021-10-19 | (주)프레이저테라퓨틱스 | p38 MAP 키나아제 억제제로 염증성 질환의 치료 효과를 나타내는 신규 화합물 |
| CN115317612A (zh) * | 2022-07-29 | 2022-11-11 | 中南大学 | 高表达热休克蛋白的巨噬细胞作为靶点在制备肝细胞癌药物中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
| TR199801361T2 (xx) | 1996-01-11 | 1998-10-21 | Smithkline Beecham Corporation | Yeni ikameli imidazol bile�imleri. |
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| CA2288741A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| CA2295762A1 (en) | 1997-07-02 | 1999-01-14 | Ravi Shanker Garigipati | Novel cycloalkyl substituted imidazoles |
| US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
| JP2002523448A (ja) | 1998-08-28 | 2002-07-30 | サイオス インコーポレイテッド | ｐ３８−αキナーゼのインヒビター |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| US6610697B1 (en) | 1999-11-10 | 2003-08-26 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods |
| CA2410509A1 (en) * | 2000-06-02 | 2001-12-13 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
| IL155570A0 (en) | 2000-11-17 | 2003-11-23 | Bristol Myers Squibb Co | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ES2295553T3 (es) * | 2002-02-12 | 2008-04-16 | Smithkline Beecham Corporation | Derivados de nicotinamida utiles como inhibidores de p38. |
| GB0209891D0 (en) * | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| AU2003298740A1 (en) * | 2002-12-05 | 2004-06-30 | Axys Pharmaceuticals, Inc. | Cyanomethyl derivatives as cysteine protease inhibitors |
| GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| BRPI0412805A (pt) * | 2003-07-23 | 2006-09-26 | Synta Pharmaceuticals Corp | método para modular canais de ìon de cálcio ativado por liberação de ìon de cálcio |
-
2004
- 2004-07-23 DE DE602004029293T patent/DE602004029293D1/de not_active Expired - Lifetime
- 2004-07-23 BR BRPI0412918-0A patent/BRPI0412918A/pt not_active IP Right Cessation
- 2004-07-23 US US10/898,581 patent/US7700622B2/en not_active Expired - Fee Related
- 2004-07-23 JP JP2006521269A patent/JP2007500129A/ja not_active Ceased
- 2004-07-23 ES ES04778988T patent/ES2315703T3/es not_active Expired - Lifetime
- 2004-07-23 MX MXPA06000915A patent/MXPA06000915A/es active IP Right Grant
- 2004-07-23 US US10/565,452 patent/US7754726B2/en not_active Expired - Fee Related
- 2004-07-23 PL PL04778988T patent/PL1687284T3/pl unknown
- 2004-07-23 CN CNA2008101343893A patent/CN101337944A/zh active Pending
- 2004-07-23 PT PT04778988T patent/PT1687284E/pt unknown
- 2004-07-23 AT AT04778988T patent/ATE412642T1/de not_active IP Right Cessation
- 2004-07-23 EP EP04778988A patent/EP1687284B1/en not_active Expired - Lifetime
- 2004-07-23 EP EP10164753A patent/EP2251333A1/en not_active Withdrawn
- 2004-07-23 AU AU2004261589A patent/AU2004261589B2/en not_active Ceased
- 2004-07-23 WO PCT/US2004/023726 patent/WO2005012241A2/en not_active Ceased
- 2004-07-23 AT AT08158865T patent/ATE482205T1/de not_active IP Right Cessation
- 2004-07-23 CN CNB2004800277979A patent/CN100447137C/zh not_active Expired - Fee Related
- 2004-07-23 EP EP08158865A patent/EP1990338B1/en not_active Expired - Lifetime
- 2004-07-23 CA CA002534990A patent/CA2534990A1/en not_active Abandoned
- 2004-07-23 DE DE602004017494T patent/DE602004017494D1/de not_active Expired - Lifetime
-
2008
- 2008-06-13 AU AU2008202641A patent/AU2008202641A1/en not_active Abandoned
-
2010
- 2010-05-28 US US12/789,949 patent/US20100234404A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500129A5 (enExample) | ||
| KR102858043B1 (ko) | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 | |
| JP6312823B2 (ja) | Ｉｌ−１２、ｉｌ−２３および／またはｉｆｎアルファ応答の調節因子として有用なアルキル−アミド−置換ピリジル化合物 | |
| JP6585231B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物 | |
| JP6259463B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 | |
| CN100355751C (zh) | 2－取代的4－杂芳基－嘧啶、其组合物及其用途 | |
| JP5717725B2 (ja) | Ｐ２Ｘ７調節因子としての５，６，７，８−テトラヒドロイミダゾ［１，２−ａ］ピラジン誘導体 | |
| JP6353529B2 (ja) | 置換されたテトラヒドロカルバゾールおよびカルバゾールカルボキサミド化合物 | |
| JP2017501234A5 (enExample) | ||
| JP6353530B2 (ja) | キナーゼ阻害剤として有用なカルバゾールカルボキサミド化合物 | |
| JP2007500129A (ja) | ｐ−３８キナーゼ阻害剤 | |
| JP2019504009A5 (enExample) | ||
| JP2009524670A5 (enExample) | ||
| CA2522435A1 (en) | Inhibitors of akt activity | |
| JP2008524246A5 (enExample) | ||
| JP2016523923A5 (enExample) | ||
| KR20180137497A (ko) | N-｛6-(2-히드록시프로판-2-일)-2-[2-(메틸술포닐)에틸]-2h-인다졸-5-일｝-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 다형체 형태 | |
| WO2010000030A1 (en) | Thiazopyrimidinones and uses thereof | |
| JP2010522711A (ja) | Ｐ２ｘ７調節因子としてのピペリジノンカルボキサミド誘導体 | |
| JP2006517976A5 (enExample) | ||
| JP2019537602A5 (enExample) | ||
| EP3870589B1 (en) | Substituted indole dimer compounds | |
| MX2015002046A (es) | Tris-(hetero)aril-pirazoles y su uso. | |
| JP2019501126A5 (enExample) | ||
| Avupati | REVIEW ON BIOACTIVE ISOXAZOLINES |